alpha Linolenic acid / Risk Cancer Research Results

aLinA, alpha Linolenic acid: Click to Expand ⟱
Features:

alpha Linolenic acid — Alpha-linolenic acid is an essential plant-derived omega-3 polyunsaturated fatty acid (PUFA; 18:3n-3) found in flax/chia, walnuts, and certain vegetable oils. It is a dietary lipid nutrient (not a regulated anticancer drug) and a metabolic precursor that can be elongated/desaturated to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), albeit inefficiently in most adults. Standard abbreviation: ALA (clarify vs “alpha-lipoic acid,” which is also abbreviated ALA in some contexts).

Primary mechanisms (ranked):

  1. Membrane phospholipid incorporation and lipid microdomain remodeling (raft-dependent signaling context-dependent)
  2. Eicosanoid and specialized pro-resolving mediator tone shift via ω-6/ω-3 substrate competition and partial conversion to EPA/DHA
  3. Inflammatory signaling modulation (e.g., NF-κB/cytokine tone; context- and tissue-dependent)
  4. PPAR signaling and lipid-metabolic reprogramming (context-dependent; often stronger for EPA/DHA than for ALA itself)
  5. Redox biology effects dominated by PUFA peroxidation susceptibility (secondary; can be protective or injurious depending on antioxidant context)

Bioavailability / PK relevance: Absorbed as a dietary fat (enhanced with meals) and incorporated into circulating lipids and cell membranes; systemic biology is dominated by tissue incorporation plus limited bioconversion. Adult conversion of ALA to EPA is typically in the single-digit to low-teens percent range, while DHA conversion is usually <1% (variable by sex, baseline diet, and competing linoleic acid intake).

In-vitro vs systemic exposure relevance: Many mechanistic “direct anticancer” effects reported in cell culture use supraphysiologic free-fatty-acid conditions (often albumin-poor) that can exaggerate lipotoxicity and lipid-peroxidation stress; in vivo effects are more plausibly mediated by membrane remodeling and lipid-mediator shifts rather than acute cytotoxicity.

Clinical evidence status: Human evidence is strongest for cardiometabolic endpoints and mortality associations; oncology-specific evidence for ALA as an anticancer intervention is limited and heterogeneous (mostly observational). Meta-analyses report mixed signals for cancer risk (including historical concern for prostate cancer in some datasets), and omega-3 supplementation trials overall have not shown clear reductions in cancer incidence; ALA-specific RCT evidence for cancer outcomes remains sparse.

Alpha Linolenic acid naturally-occurring fatty acid. Found in vegetable oils, plant oils, nuts and meat.
• Alpha linolenic acid (ALA) is an essential omega-3 fatty acid commonly found in plant sources such as flaxseed, chia seeds, walnuts, and certain vegetable oils.
• As an essential fatty acid, ALA must be obtained from the diet and serves as a precursor to longer-chain omega-3 fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
• While ALA itself is not a strong antioxidant, its downstream metabolites can indirectly support antioxidant defense systems.
• By reducing oxidative stress, ALA may help protect cellular DNA from damage that can trigger carcinogenesis.

Alpha-linolenic acid (ALA) mechanistic axes relevant to cancer biology

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Membrane lipid remodeling and lipid microdomains Growth signaling platforms ↔ (context-dependent); receptor clustering may shift Membrane fluidity ↑ R, G Signal microenvironment modulation Central “direct” mechanism for ALA is incorporation into phospholipids; downstream signaling changes are model- and composition-dependent and may be stronger after partial conversion to EPA.
2 Eicosanoid balance and lipid mediator tone Pro-inflammatory eicosanoids ↓ (context-dependent) Inflammation resolution tone ↑ (context-dependent) G Lipid mediator rebalancing ALA competes with ω-6 substrates and can modestly raise EPA; DHA rise is usually minimal, limiting DHA-linked effects.
3 NF-κB and cytokine signaling NF-κB ↓ or ↔ (model-dependent) Inflammatory tone ↓ (context-dependent) R, G Anti-inflammatory modulation Often secondary to lipid-mediator shifts and membrane effects; direction can vary by cell type and stimulus.
4 PPAR axis and lipid metabolism programs PPAR signaling ↔ or ↑ (context-dependent); lipid metabolism rewiring Metabolic flexibility ↑ G Transcriptional metabolic modulation PPAR effects are well-established for fatty-acid ligands broadly; relative potency may be higher for long-chain ω-3s than for ALA.
5 AMPK and energy-stress signaling AMPK ↑ (context-dependent) Energy homeostasis support ↔ R, G Metabolic checkpoint engagement Reported in some systems, but less consistent than for EPA/DHA; may couple to downstream mTOR tone in select models.
6 PI3K AKT mTOR Survival signaling ↓ (model-dependent) ↔ R, G Growth pathway modulation Usually secondary to membrane composition and inflammatory tone; not a universal primary mechanism.
7 ROS and lipid peroxidation susceptibility ROS ↑ (high concentration only) or ↔; lipid peroxidation ↑ (context-dependent) Oxidative injury ↔ or ↑ (context-dependent) P, R, G Redox stress or redox buffering PUFAs are oxidation-prone; outcomes depend strongly on antioxidant capacity, iron availability, and culture vs in vivo context.
8 Apoptosis and mitochondrial integrity Apoptosis ↑ (model-dependent) ↔ G Cell fate shift Often downstream of membrane/redox changes; direct cytotoxicity is more likely under non-physiologic in-vitro conditions.
9 Angiogenesis and VEGF axis VEGF ↓ (model-dependent) ↔ G Pro-angiogenic signaling dampening Frequently secondary to inflammatory signaling shifts rather than a direct ALA-specific target.
10 HIF-1α and hypoxia programs HIF-1α ↓ (model-dependent) ↔ G Stress-adaptation modulation May track with changes in inflammatory/redox tone; evidence is preclinical and context-sensitive.
11 Chemosensitization Therapy response ↑ (context-dependent) — G Adjunct response modulation Signals exist for ω-3s broadly, but ALA-specific and clinically reproducible effects are uncertain.
12 Clinical Translation Constraint EPA/DHA conversion limited; competing linoleic acid can reduce conversion Diet- and phenotype-dependent exposure — PK and biology constraint Many endpoints attributed to ω-3 biology are driven more robustly by EPA/DHA; ALA’s impact depends on dose, background diet, and individual metabolism.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (lipid incorporation begins; oxidative interactions)
  • R: 30 min–3 hr (early signaling + inflammatory shifts)
  • G: >3 hr (membrane remodeling, phenotype-level effects)

Alpha-linolenic acid (ALA) axes relevant to Alzheimer’s disease biology

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Brain lipid supply and membrane composition ↔ to ↑ (context-dependent) Supports neuronal/glial membrane lipid remodeling ALA is a precursor pool; central effects depend on dietary intake, transport, and limited conversion to EPA/DHA. DHA accretion from ALA is typically minimal in adults.
2 Neuroinflammation and microglial activation tone ↓ or ↔ (context-dependent) Dampens pro-inflammatory signaling in some models Often mediated indirectly via ω-6/ω-3 substrate competition and downstream lipid mediator balance; genotype (e.g., APOE) and baseline diet may modify effects.
3 Blood–brain barrier integrity and neurovascular unit ↑ (context-dependent) Barrier support, vascular inflammation reduction Preclinical and mechanistic literature suggests lipid composition influences BBB properties; clinical specificity for ALA remains uncertain.
4 Aβ production/clearance balance ↔ (model-dependent) Potential shift in amyloidogenic processing or clearance pathways Evidence is heterogeneous; effects reported for ω-3 biology are more consistently linked to DHA/EPA than to ALA per se.
5 Tau phosphorylation and proteostasis stress responses ↔ (model-dependent) Possible modulation of kinase/phosphatase balance and stress signaling Not a well-established primary ALA target; if present, likely secondary to inflammatory/metabolic tone shifts.
6 Brain energy metabolism and insulin signaling ↔ to ↑ (context-dependent) Supports metabolic resilience (glucose handling) in some contexts Human biomarker studies often focus on EPA/DHA; ALA associations may reflect broader dietary patterns and fatty-acid network effects.
7 ROS and lipid peroxidation ↔ (context-dependent); lipid peroxidation risk ↑ (oxidative, low-antioxidant contexts) Shifts ROS production vs oxidation susceptibility ALA can reduce inflammation-linked ROS generation in some settings, but as an unsaturated PUFA it increases oxidizable substrate; net “ROS injury” depends on redox/iron/antioxidant context and whether ALA is membrane-incorporated vs free fatty acid.
8 Synaptic plasticity and neurotransmission support ↔ to ↑ (context-dependent) Potential support for synaptic function via membrane effects More robust evidence exists for DHA in synaptic membranes; ALA may contribute indirectly or in deficiency/low ω-3 states.
9 Clinical Translation Constraint — Exposure and effect-size limitation ALA-specific cognitive/AD trial evidence is limited; conversion to DHA is typically very low, and background linoleic acid intake can reduce long-chain ω-3 formation.


Risk, Risk: Click to Expand ⟱
Source:
Type:
Risk: by definition reduces risk of disease or cancer.
Down Target direction of risk indicates lower cancer risk.
ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive. 
Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral




CRIS Exposure / Compound Evidence Cancers Notes




-5 Exercise (overall)
VStrong Hum BC, CRC, Endo, PCa, Liv






-5 Aerobic + resistance VStrong Hum Broad inc + mort






-4 Aerobic exercise (mod–vig) VStrong Hum BC, CRC, Endo






-4 Resistance training (alone) Strong Hum BC, CRC






-3 High-intensity interval training Mod–Strong Hum BC, CRC






-2 NEAT / low-intensity activity Moderate Hum CRC






-5 Cruciferous vegetable pattern Strong Hum Lung, CRC, BC, PCa






-5 Sunlight exposure (physiologic) Strong Hum CRC, BC, PCa






-4 Fasting (metabolic pattern)
Strong Mech + Hum BC, CRC, PCa 






-4 Curcumin
Hum + Pre GI, BC, PCa






-4 Sulforaphane
Hum + Pre Lung, CRC, BC






-4 PEITC
Hum + Pre Lung, CRC, PCa






-4 EGCG (tea matrix)
Strong Hum GI, PCa, BC






-4 Lycopene
Strong Hum PCa






-4 Apigenin
Pre + Diet Hum BC, PCa, CRC 






-4 Luteolin
Pre + Diet Hum Lung, CRC, BC 






-4 Kaempferol
Diet Hum Ov, Panc, Lung






-4 Fisetin
Pre + Early Hum CRC, PCa, Mel






-4 Ellagic acid → Urolithin A
Hum (microbiome) CRC, PCa, BC






-3 Omega-3 (EPA/DHA)
Strong Hum CRC, BC






-3 Vitamin D3 (supp)
Obs + RCT CRC, BC






-3 Garlic (allicin)
Mod Hum GI






-3 Mushroom beta-glucans
Hum adjunct GI, BC






-3 Melatonin
Hum + Mech BC, PCa






-3 Coffee (whole)
Strong Hum Liv, Endo






-2 Quercetin
Limited Hum Lung, CRC






-2 Resveratrol
Limited Hum CRC, BC






-2 I3C / DIM
Mod Hum BC, Cerv






-2 Thymoquinone
Early Hum BC, CRC






-2 Beta-carotene (food)
Hum Lung






-1 Vitamin K2 (MK-4/7)
Limited Hum Liv, PCa






-1 Boron
Obs PCa, Lung






0 Vitamin C (oral)
Strong Hum —






0 Genistein (soy)
Strong Hum BC, PCa






0 Selenium (diet)
Mixed Hum PCa






0 Capsaicin
Mixed Gastric






+2 Vitamin E (alpha only)
Strong RCT PCa






+2 Green tea extract (high-dose)
Case reports Liv






+4 Beta-carotene (supplement)
Strong RCT Lung (smokers)






+5 Alcohol (ethanol)
Strong Hum BC, Liv, Eso







Evidence
Hum        human data
VStrong    very strong
Strong     strong
Mod        moderate
Obs        observational
Pre        preclinical
RCT        randomized controlled trial
Mech       mechanistic
Adjunct    adjunct clinical use


Scientific Papers found: Click to Expand⟱
5262- aLinA,    The Role of Alpha-Linolenic Acid and Other Polyunsaturated Fatty Acids in Mental Health: A Narrative Review
- Review, AD, NA
*neuroP↑, *Risk↓, *cognitive↑, *Inflam↓, *antiOx↑, *BDNF↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   neuroP↑, 1,   Risk↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: Risk, Risk
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:116  Target#:785  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page